Skip to main content
SpringerLink
Log in

Acquired immunodeficiency syndrome-related lymphoma

  • Chapter
  • First Online:
Management of Lymphomas: A Case-Based Approach

  • 717 Accesses

Abstract

Patient X is a 50-year-old man who presented to his primary care physicians with rapidly progressing right cervical lymphadenopathy. The patient underwent an excisional biopsy, which was consistent with diffuse large B-cell lymphoma (DLBCL).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Centers for Disease Control (CDC). Pneumocystis pneumonia–Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30:1–3.

    Google Scholar 

  2. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at-risk for AIDS. Science. 1984;224:500–503.

    Google Scholar 

  3. World Health Organization. Global Health Observatory (GHO) data: HIV/AIDS. http://www.who.int/gho/hiv/en/. Accessed March 7, 2017.

  4. Centers for Disease Control and Prevention. HIV/AIDS: HIV prevalence estimate. http://www.cdc.gov/hiv/statistics/overview/. Accessed March 7, 2017.

  5. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–432.

    Google Scholar 

  6. Achenbach CJ, Buchanan AL, Cole SR, Hou L, et al. HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis. 2014;58:1599.

    Google Scholar 

  7. National Cancer Institute. SEER stat fact sheets: non-Hodgkin lymphoma. http://seer.cancer.gov/statfacts/html/nhl.html. Accessed March 7, 2017.

  8. Bibas M and Antinori A. EBV and HIV-related lymphoma. Mediterr J Hematol Infect Dis. 2009;1:e2009032.

    Google Scholar 

  9. Centers for Disease Control. 1993 revised classification for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:961–962.

    Google Scholar 

  10. Gucalp A, Noy A. Spectrum of HIV lymphoma 2009. Curr Opin Hematol. 2010;17:362–367.

    Google Scholar 

  11. Swerdlow SH, Campo E, Harris NL, et al (eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Vol 2. Lyon, France: IARC Press 2008.

    Google Scholar 

  12. Epeldegui M, Vendrame e, Martinez-Maza O. HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res. 2010;48:72–83.

    Google Scholar 

  13. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108:3786.

    Google Scholar 

  14. Carbone J, Cesarman E, Spina, M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113:1213–1224.

    Google Scholar 

  15. Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood. 1992;80:8–20.

    Google Scholar 

  16. Vishnu P, Aboulafia DM. AIDS-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy. Adv Hematol. 2012;2012:485943.

    Google Scholar 

  17. Vishnu P, Aboulafia DM. AIDS-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy. Adv Hematol. 2012;2012:485943.

    Google Scholar 

  18. Thompson LD, Fisher SI, Chu WS, Nelson A, Abbondanzo SL. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol. 2004;121:727–738.

    Google Scholar 

  19. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and decarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin’s disease: a prospective multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24:444–450.

    Google Scholar 

  20. Martis N, Mounier N. Hodgkin lymphoma in patients with HIV infection. Curr Hematol Malg Rep. 2012;7:228–234.

    Google Scholar 

  21. Levine AM. Management of AIDS-related lymphoma. Curr Opin Oncol. 2008;20:522–528.

    Google Scholar 

  22. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, et al. AIDS-related lymphoma: histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Path. 1991;138:149–163.

    Google Scholar 

  23. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. New Engl J Med. 1997;336:1641–1648.

    Google Scholar 

  24. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. New Engl J Med. 1994;329:987–994.

    Google Scholar 

  25. Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer. 1999;86:2391–2397.

    Google Scholar 

  26. Bower M, Bazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non- Hodgkin lymphoma treated in the era of highly arctive antiretroviral therapy. Ann Intern Med. 2005;143:265–273.

    Google Scholar 

  27. Boué F, Gabarre J, Gisselbrecht C, et al. Phase II trials of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:4123–4128.

    Google Scholar 

  28. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium trial 010. Blood. 2005;106:1538–1543.

    Google Scholar 

  29. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral suspension and tumor biology. Blood. 2003;101:4653–4659.

    Google Scholar 

  30. Sparano JA, Lee JY, Kaplan, LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008–3016.

    Google Scholar 

  31. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and shortcourse EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115:3017–3024.

    Google Scholar 

  32. Noy A, Kaplan L, Lee JY. A modified dose-intensive CODOX-M/IVAC for HIV-associated Burkitt lymphoma and atypical Burkitt lymphoma (BL) demonstrates high cure rates and low toxicity: prospective multicenter trial of the AIDS Malignancy Consortium (AMC 048). Blood. 2013;122:639.

    Google Scholar 

  33. Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-associated Burkitt lymphoma: Good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART era. Adv Hematol. 2012;2012:735392.

    Google Scholar 

  34. Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/ IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma. AIDS. 2010;24:851–856.

    Google Scholar 

  35. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired-immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94:1492–1499.

    Google Scholar 

  36. Kojima Y, Hagiwara S, Uehira T, et al. Clinical outcomes of AIDS-related Burkitt lymphoma: A multi-institution retrospective survey in Japan. Jpn J Clin Oncol. 2014;44:318–323.

    Google Scholar 

  37. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. New Engl J Med. 2013;369:1915–1925.

    Google Scholar 

  38. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associate non- Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122:3251–3262.

    Google Scholar 

  39. Dunleavy K, Wilson WH. The case for rituximab in AIDS-related lymphoma. Blood. 2006;107:3014–3015.

    Google Scholar 

  40. Kaplan LD. Management of HIV-associated Hodgkin lymphoma: How far we have come. J Clin Oncol. 2012;30:4056–4058.

    Google Scholar 

  41. Xicoy B, Miralles P, Morgades M, Rubio R, Valencia ME, Ribera JM. Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin’s lymphoma treated with doxorubicin, bleomycin, vinblastine, dacarbazine. Haematologica. 2013;98:e85–e86

    Google Scholar 

  42. Spina M, Gabare J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100:1984–1988.

    Google Scholar 

  43. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol. 2003;14:1562–1569.

    Google Scholar 

  44. Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Results of a prospective multicenter study. J Clin Oncol. 2012;30:4117–4123.

    Google Scholar 

  45. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New Engl J Med. 1995;333:1540–1545.

    Google Scholar 

  46. Nademanee A, O’Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. Blood. 1995;85:1381–1390.

    Google Scholar 

  47. Gabarre J, Leblond V, Sutton L, et al. Autologous bone marrow transplantation in relapsed HIVrelated non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1996;18:1195–1197.

    Google Scholar 

  48. Gabarre J, Azar N, Autran B, Katlama C, Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. The Lancet. 2000;355:1071–1072.

    Google Scholar 

  49. Molina A, Krishnan AY, Nademanee A, et al. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer. 2000;89:680–689.

    Google Scholar 

  50. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105:874–878.

    Google Scholar 

  51. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stemcell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003;21:4423–4427.

    Google Scholar 

  52. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica. 2004;89:1100–1108.

    Google Scholar 

  53. Serrano D, Carrión R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005;33:487–494.

    Google Scholar 

  54. Spritzer TR, Ambinder RF, Lee JY, Ket al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14:59–66.

    Google Scholar 

  55. Re A, Michieli M, Casari s, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group of AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114:1306–1313.

    Google Scholar 

  56. Balsalobre P, Díez-Martín JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009;27:2192–2198.

    Google Scholar 

  57. Alvarnas J, Le Rademacher J, Wang Y, et al. Autologous hematopoietic stem cell transplantation (AHCT) in patients with chemotherapy-sensitive, relapsed/refractoary (CSRR) Human Immunodeficiency virus-related lymphoma (HAL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) trial. Blood. 2014; Abstract 674.

    Google Scholar 

  58. Krishnan A, Palmer JP, Zaia JA, Tsai NC, Alvarnas M, Forman SJ. HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant. 2010;16:1302–1308.

    Google Scholar 

  59. Díez-Martín JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- non- Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113:6011–6014.

    Google Scholar 

  60. Re A, Cattaneo C, Skert C, et al. Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica. 2013;98:1762–1768.

    Google Scholar 

  61. Attolico I, Pavone V, Ostuni An, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol blood Marrow Transplant. 2012;18:241–249.

    Google Scholar 

  62. Giri N, Vowels MR, Ziegler JB. Failure of allogeneic bone marrow transplantation to benefit HIV infection. J Paediatr Child Health. 1992;28:331–333.

    Google Scholar 

  63. Contu L, La Nasa G, Arras M, et al. Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone Marrow Transplant. 1993;12:669–671.

    Google Scholar 

  64. Gupta V, Tomblyn M, Pedersen TL, et al. Allogeneic hematopoietic cell transplantation in HIV-positive patients with hematological disorders: a report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2009;15: 864–871.

    Google Scholar 

  65. Hütter G, Zaia JA. Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol. 2011;163:284–295.

    Google Scholar 

  66. Moh R, Danel C, Sorho S, et al. Haematological changes in adults receiving a zidovudinecontaining HAART regimen in combination with cotrimoxazole in Cote d’Ivoire. Antiviral Therapy. 2004;10:615–624.

    Google Scholar 

  67. Cingolani A, Torti L, Pinnetti C, et al. Detrimental clinical interaction between ritonavirboosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin’s lymphoma. AIDS. 2010;24:2408–2412.

    Google Scholar 

  68. Torres HA, Rallapalli V, Saxena A, et al. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbial Infect. 2014;20:672–679.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duarte, USA

    Joseph Alvarnas

Authors
  1. Joseph Alvarnas
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. City of Hope Hospital, Duarte, California, USA

    Jasmine Zain

  2. Toni Stephenson Lymphoma Center, City of Hope Hospital, Duarte, California, USA

    Larry W. Kwak

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Alvarnas, J. (2017). Acquired immunodeficiency syndrome-related lymphoma. In: Zain, J., Kwak, L. (eds) Management of Lymphomas: A Case-Based Approach. Adis, Cham. https://doi.org/10.1007/978-3-319-26827-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26827-9_13

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-26825-5

  • Online ISBN: 978-3-319-26827-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation